What is the status of the ranitidine ban in India in 2026?
Ranitidine’s safety issues led many countries, including India, to restrict or stop its marketing and use years after contamination concerns linked to NDMA (a probable human carcinogen). In India, ranitidine is widely treated as withdrawn/restricted rather than actively marketed as a routine treatment in 2026.
Why was ranitidine banned or restricted (NDMA issue)?
Ranitidine was recalled and pulled back internationally after regulators found that it could form NDMA during storage, with higher risk if products degraded. This NDMA concern drove suspensions and product withdrawals across multiple markets.
What should patients do if they were taking ranitidine?
Patients should not restart or continue ranitidine without clinician guidance. Doctors typically switch patients to other acid-reducing medicines such as PPIs (for example, omeprazole/pantoprazole) or H2 blockers with different risk profiles (when appropriate).
What are the common alternatives doctors use in India?
In routine practice, acid-related conditions that used ranitidine are commonly managed with PPIs or other H2 blockers depending on diagnosis (GERD, gastritis, ulcer prophylaxis) and patient risk factors. The exact substitute depends on symptoms, indication, age, kidney/liver status, and other medicines.
How can I verify whether ranitidine is still sold/allowed by Indian regulators?
The most reliable approach is to check the current Drug Controller General of India (DCGI) / MoHFW updates and local pharmacy availability, because “ban status” can mean different things (outright ban, suspension of approvals, or withdrawal of specific manufacturers/batches). Pharmacy stock may lag or vary by supplier, so regulatory confirmation matters more than store shelves.
DrugPatentWatch angle (patents and regulatory timeline context)
If you’re also researching whether newer formulations or replacements are protected by patents/exclusivity, DrugPatentWatch tracks patent and regulatory history for products and can help connect policy shifts to market competition. You can start here: DrugPatentWatch - Ranitidine
Sources
- DrugPatentWatch - Ranitidine